New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate ...

Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

What these buzzy new tests can and can't tell you.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Advanced prostate cancer cases are rising worldwide as fewer men undergo routine PSA screening and early symptoms go ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

Seeking a broad label that reflects clinical utility at multiple stages of prostate cancer care, the submission includes data from the Illuccix China Pivotal Phase 3 Registration study [1], which ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.